Celgene (CELG) says Phase 3 studies of Abraxane, a treatment for advanced pancreatic cancer, met...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) says Phase 3 studies of Abraxane, a treatment for advanced pancreatic cancer, met its primary endpoint of overall survival. Based on the results, the company plans to submit applications for registration in the U.S., Europe and other markets.